yingweiwo

(R)-Monlunabant ((R)-MRI-1891)

Alias: (R)-Monlunabant; (R)-MRI-1891; (R)-MRI1891; 2765579-76-6;
(R)-Monlunabant ((R)-MRI-1891) is a CB1 receptor modulator utilized in study/research of obesity and metabolic diseases.
(R)-Monlunabant ((R)-MRI-1891)
(R)-Monlunabant ((R)-MRI-1891) Chemical Structure CAS No.: 2765579-76-6
Product category: Cannabinoid Receptor
This product is for research use only, not for human use. We do not sell to patients.
Size Price Stock Qty
5mg
10mg
50mg
100mg
Other Sizes

Other Forms of (R)-Monlunabant ((R)-MRI-1891):

  • Monlunabant ((S)-MRI-1891)
Official Supplier of:
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Top Publications Citing lnvivochem Products
Product Description
(R)-Monlunabant ((R)-MRI-1891) is a CB1 receptor modulator utilized in study/research of obesity and metabolic diseases.
Biological Activity I Assay Protocols (From Reference)
These protocols are for reference only. InvivoChem does not independently validate these methods.
Physicochemical Properties
Molecular Formula
C26H22CLF3N6O3S
Molecular Weight
591
Elemental Analysis
C, 52.84; H, 3.75; Cl, 6.00; F, 9.64; N, 14.22; O, 8.12; S, 5.42
CAS #
2765579-76-6
Related CAS #
Monlunabant;2712480-46-9; (R)-Monlunabant;2765579-76-6; 1610420-66-0 (racemic); 2244778-08-1
Appearance
White to off-white solid
SMILES
O=S(N/C(N1N=C(C2=CC=C(C=C2)Cl)[C@H](C3=CC=CC=C3)C1)=N/C(NC(C)=O)=N)(C4=CC=C(C=C4)C(F)(F)F)=O
Synonyms
(R)-Monlunabant; (R)-MRI-1891; (R)-MRI1891; 2765579-76-6;
HS Tariff Code
2934.99.9001
Storage

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Shipping Condition
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
Solubility Data
Solubility (In Vitro)
DMSO: ~100 mg/mL (~169.2 mM; with ultrasonication)
Solubility (In Vivo)
Solubility in Formulation 1: 2.5 mg/mL (4.23 mM) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution; with ultrasonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.

Solubility in Formulation 2: 2.5 mg/mL (4.23 mM) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution; with ultrasonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of corn oil and mix well.

 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 1.6920 mL 8.4602 mL 16.9205 mL
5 mM 0.3384 mL 1.6920 mL 3.3841 mL
10 mM 0.1692 mL 0.8460 mL 1.6920 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.

Calculator

Molarity Calculator allows you to calculate the mass, volume, and/or concentration required for a solution, as detailed below:

  • Calculate the Mass of a compound required to prepare a solution of known volume and concentration
  • Calculate the Volume of solution required to dissolve a compound of known mass to a desired concentration
  • Calculate the Concentration of a solution resulting from a known mass of compound in a specific volume
An example of molarity calculation using the molarity calculator is shown below:
What is the mass of compound required to make a 10 mM stock solution in 5 ml of DMSO given that the molecular weight of the compound is 350.26 g/mol?
  • Enter 350.26 in the Molecular Weight (MW) box
  • Enter 10 in the Concentration box and choose the correct unit (mM)
  • Enter 5 in the Volume box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 17.513 mg appears in the Mass box. In a similar way, you may calculate the volume and concentration.

Dilution Calculator allows you to calculate how to dilute a stock solution of known concentrations. For example, you may Enter C1, C2 & V2 to calculate V1, as detailed below:

What volume of a given 10 mM stock solution is required to make 25 ml of a 25 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=25 μM, V2=25 ml and V1 is the unknown:
  • Enter 10 into the Concentration (Start) box and choose the correct unit (mM)
  • Enter 25 into the Concentration (End) box and select the correct unit (mM)
  • Enter 25 into the Volume (End) box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 62.5 μL (0.1 ml) appears in the Volume (Start) box
g/mol

Molecular Weight Calculator allows you to calculate the molar mass and elemental composition of a compound, as detailed below:

Note: Chemical formula is case sensitive: C12H18N3O4  c12h18n3o4
Instructions to calculate molar mass (molecular weight) of a chemical compound:
  • To calculate molar mass of a chemical compound, please enter the chemical/molecular formula and click the “Calculate’ button.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
  • Molecular mass (or molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
  • Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
/

Reconstitution Calculator allows you to calculate the volume of solvent required to reconstitute your vial.

  • Enter the mass of the reagent and the desired reconstitution concentration as well as the correct units
  • Click the “Calculate” button
  • The answer appears in the Volume (to add to vial) box
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal to make allowance for loss during the experiment)
Step 2: Enter in vivo formulation (This is only a calculator, not the exact formulation for a specific product. Please contact us first if there is no in vivo formulation in the solubility section.)
+
+
+

Calculation results

Working concentration: mg/mL;

Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.

(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
             (2) Be sure to add the solvent(s) in order.

Clinical Trial Information
# Monlunabant (INV-202 / MRI-1891 / NN9440, peripherally restricted oral CB1 inverse agonist, Novo Nordisk/Inversago Pharma)

A Research Study Investigating Safety and Concentration in the Blood After One Dose Tablet of the New Medicine Monlunabant in Healthy Weight Japanese and Caucasian Men
CTID: NCT06542536
Phase: Phase 1
Status: Completed
Date: 2025-11-18
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of Two Doses of INV-202 in Patients with Diabetic Kidney Disease
EudraCT: 2022-002140-51
Phase: Phase 2
Status: Completed
Date: 2022-12-21
Single Oral Ascending Dose First-in-Human Phase 1 Safety, Tolerability and PK Study of Monlunabant in Caucasian Healthy Volunteers
CTID: Not Applicable
Phase: Phase 1 SAD
Status: Completed
Date: 2022
Phase 1 MAD Multiple Daily Dosing PK/PD Trial Measuring Peripheral CB1 Target Engagement, Lipid & Glucose Biomarker Shifts in Overweight Healthy Subjects
CTID: Not Applicable
Phase: Phase 1 MAD
Status: Completed
Date: 2023
Phase 1 Ethnic Crossover PK Trial Comparing Monlunabant Exposure in Japanese vs Caucasian Healthy Male Volunteers
CTID: NCT06542536
Phase: Phase 1 Ethnic PK
Status: Completed
Date: 2024-10-24
Phase 1 Crossover Substudy Evaluating Food Effect, Mild Hepatic and Renal Impairment on Oral Monlunabant Systemic Exposure
CTID: Not Applicable
Phase: Phase 1 PK Substudy
Status: Completed
Date: 2024
Multicenter Randomized Double-Blind Placebo-Controlled Phase 2a Dose-Ranging Trial of Once-Daily Oral Monlunabant for Adults With Obesity and Metabolic Syndrome (Primary Endpoint: 16-Week Body Weight Change)
CTID: NCT05891834
Phase: Phase 2a
Status: Completed, Positive Weight-Loss Primary Endpoint
Date: 2024-08-22
Multinational Randomized Double-Blind Phase 2b Global Obesity Long-Term Efficacy & Safety Extension Trial of Monlunabant Low/High Dose Regimens
CTID: Not Applicable
Phase: Phase 2b
Status: Active, Recruiting
Date: 2025
Randomized Double-Blind Placebo-Controlled Phase 2 NEWS Trial of Monlunabant in Adults With Diabetic Nephropathy (Primary Renal Fibrosis & Albuminuria Endpoints)
CTID: NCT05514548
Phase: Phase 2 Renal
Status: Completed, Missed Primary Efficacy Endpoint
Date: 2025
Exploratory Phase 2 Pilot Trial of Monlunabant for Non-Alcoholic Steatohepatitis (NASH) in Overweight Type 2 Diabetes Patients
CTID: Not Applicable
Phase: Phase 2 Pilot Hepatic
Status: Initiated, Not Recruiting
Date: 2026
Long-Term Open-Label Phase 2 Extension Safety Study for Participants Who Completed Phase 2a Obesity Core Trial
CTID: Not Applicable
Phase: Phase 2 Extension
Status: Ongoing
Date: 2025
Preclinical In Vitro CB1/CB2 Receptor Binding & Functional Assay Profiling Monlunabant Peripheral Restriction, Minimal Blood-Brain Barrier Permeability vs Rimonabant
CTID: Not Applicable
Phase: Preclinical Biochemical
Status: Completed
Date: 2020
In Vivo Diet-Induced Obese Mouse Efficacy Preclinical Study of Oral Monlunabant for Weight Loss, Insulin Sensitization and Adipose Tissue Lipolysis
CTID: Not Applicable
Phase: Preclinical Metabolic Efficacy
Status: Completed
Date: 2021
STZ Diabetic Nephropathy Rodent Preclinical Trial of Chronic Monlunabant to Reduce Renal Fibrosis and Urinary Albumin Excretion
CTID: Not Applicable
Phase: Preclinical Renal Efficacy
Status: Completed
Date: 2022
28-Day & 90-Day Repeat Oral Dose Toxicology Preclinical Trial of Monlunabant in Rats and Cynomolgus Monkeys Assessing Hepatic, Gastrointestinal and CNS Safety Endpoints
CTID: Not Applicable
Phase: Preclinical Toxicology
Status: Completed
Date: 2022
Radiolabeled [¹⁴C]-Monlunabant Whole-Body ADME & Tissue Distribution Preclinical Study Confirming Minimal Central Nervous System Tissue Penetration
CTID: Not Applicable
Phase: Preclinical ADME
Status: Completed
Date: 2023
Contact Us